Avanir comprehensively reevaluated the U.S. migraine medication market. As a result, the decision was made to terminate the licensing agreement
1.
Optinose (NASDAQ:OPTN), received written notice from Avanir Pharmaceuticals, Inc. of its election to terminate the License Agreement to develop and commercialize ONZETRA® XSAIL® (Sumatriptan) in the United States, Canada, and Mexico. As a result, the License Agreement is expected to terminate on March 10, 2019
2.
Through September 30, 2018, under the terms of the License Agreement with Avanir, Optinose has received aggregate cash payments of $70 million in connection with the initial signing and subsequent payments
2.
1
https://www.otsuka.co.jp/en/company/newsreleases/2018/20181211_1.html
2
https://globenewswire.com/news-rele...Avanir-Pharmaceuticals-for-ONZETRA-XSAIL.html